Banque Cantonale Vaudoise Has $547,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Banque Cantonale Vaudoise raised its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 6.7% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,017 shares of the medical research company’s stock after purchasing an additional 126 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Charles River Laboratories International were worth $547,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of CRL. VisionPoint Advisory Group LLC boosted its position in Charles River Laboratories International by 105.7% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after buying an additional 74 shares during the last quarter. Operose Advisors LLC bought a new position in Charles River Laboratories International in the third quarter valued at approximately $42,000. Brown Brothers Harriman & Co. grew its holdings in Charles River Laboratories International by 76.0% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after acquiring an additional 95 shares during the period. GAMMA Investing LLC bought a new stake in shares of Charles River Laboratories International during the 4th quarter valued at $62,000. Finally, Bruce G. Allen Investments LLC acquired a new position in shares of Charles River Laboratories International in the 4th quarter valued at $70,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the subject of a number of recent analyst reports. The Goldman Sachs Group began coverage on Charles River Laboratories International in a report on Thursday, June 6th. They issued a “buy” rating and a $290.00 price objective for the company. TheStreet upgraded shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a research report on Friday, March 1st. TD Cowen decreased their price objective on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a report on Monday, May 13th. Argus increased their target price on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, March 18th. Finally, Mizuho initiated coverage on shares of Charles River Laboratories International in a report on Friday, June 7th. They issued a “neutral” rating and a $235.00 price target for the company. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus target price of $256.38.

Charles River Laboratories International Stock Up 0.9 %

Charles River Laboratories International stock opened at $211.60 on Friday. The company has a fifty day simple moving average of $222.48 and a 200 day simple moving average of $232.55. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00. The company has a market cap of $10.90 billion, a P/E ratio of 24.89, a price-to-earnings-growth ratio of 1.98 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.05 by $0.22. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $997.24 million. Research analysts anticipate that Charles River Laboratories International, Inc. will post 11 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Joseph W. Laplume sold 1,304 shares of the business’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $226.97, for a total transaction of $295,968.88. Following the transaction, the executive vice president now directly owns 23,276 shares in the company, valued at $5,282,953.72. The sale was disclosed in a filing with the SEC, which is available through this link. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).